RNAi-mediated inhibition of histamine receptor H1-related conditions
US8222227B2 · kind B2 · utility
2Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2011 |
| Grant date | Jul 17, 2012 |
| Priority date | — |
| Expiry date | Jun 30, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.